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Summary 
Platelet expressed G protein-coupled receptors (GPCRs) are critical regulators of platelet 
function.    Pharmacological blockade of these receptors forms a powerful therapeutic tool in the 
treatment and prevention of arterial thrombosis associated with coronary atherosclerosis and 
ischaemic stroke.  However, anti-thrombotic drug therapy is associated with high inter-patient 
variability in therapeutic response and adverse bleeding side-effects.  In order to optimise the use 
of existing antiplatelet drugs and to develop new therapies more detailed knowledge is required 
relating to the molecular mechanisms that regulate GPCR and therefore platelet function. One 
approach has been to identify rare, function-disrupting mutations within key platelet proteins in 
patients with bleeding disorders. In this review we describe how an integrated functional 
genomics strategy has contributed important structure-function information about platelet 
GPCRs with specific emphasis upon purinergic (P2Y12) and thromboxane (TP-Į) receptors. We 
also discuss the potential implications these findings have for pharmacotherapy and for 
understanding the molecular basis of mild bleeding disorders. 
 
 
Abbreviations 
GPCR, G Protein-Coupled Receptor; ECL, Extracellular loop; ICL, Intracellular loop; TMD, 
Transmembrane domain;  
 
 
Introduction 
Platelets are small anucleate cells derived from megakaryocytes in the bone marrow that 
circulate in the bloodstream and play a key role in haemostasis. Under physiological conditions 
platelets do not adhere to the vessel wall due to continual release of inhibitory prostaglandins and A
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nitric oxide which prevent platelet activation.  When damage to the vasculature occurs, platelets 
bind to exposed collagen, become activated and release a number of stimulatory mediators which 
feedback in an autocrine manner to cause further platelet activation, recruitment of more platelets 
to the site of injury and the formation of a stable clot, preventing further blood loss (Kaplan et 
al., 2011).  
Platelet activation is a tightly regulated process with both increased and decreased platelet 
reactivity resulting in significant sequelae.  Decreased platelet activity is associated with an 
increased risk of bleeding. Conversely increased platelet activity, for example in response to 
atherosclerotic plaque rupture, can lead to the build-up of vessel-occluding thrombi, resulting in 
myocardial infarction or stroke. The majority of drugs that target platelets inhibit platelet 
activation. However a key challenge of pharmacotherapy in this area is to achieve sufficient 
inhibition of platelet activity to prevent thrombus formation whilst maintaining the haemostatic 
properties of platelets in order to avoid excessive bleeding.  Although the main signalling 
pathways underlying platelet activation are now well defined (Stegner et al., 2011) further 
understanding of how platelet receptors are regulated, together with the identification of novel 
platelet proteins will aid the development of anti-platelet drugs with a better therapeutic index. 
Furthermore, with the development of rapid and detailed phenotypic and genotypic analyses 
there is also scope for tailoring therapy to the individual.  
The aim of this review is to focus on rare, function-disrupting variants of platelet GPCRs and to 
discuss the significance of these findings in relation to GPCR structure / function and their 
potential implications for pharmacological therapy.  
 
Platelet GPCRs and platelet activation pathways 
There are a number of GPCRs present on the platelet cell surface including two purinergic 
receptors, P2Y1 and P2Y12, proteinase activated receptors (PAR) 1 and 4,  thromboxane receptor 
A2 receptor (TP-Į VHURWRQHUJLF receptor 5HT2A, prostacyclin receptor (IP1), prostaglandin 
receptor E2 (EP3DQGĮ2A adrenoceptor (Offermanns, 2006).  There is also some evidence for the 
expression of other GPCRs in human platelets at the mRNA level although this is not backed by A
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conclusive evidence either through  pharmacological or protein expression studies (Rowley et 
al., 2011).  Of the GPCRs present on the platelet surface the key receptors involved in platelet 
activation are PAR1, PAR4, P2Y1, P2Y12 and TP-Į2f these the P2Y12 receptor is an established 
anti-thrombotic drug target whilst the PAR1 antagonist, Vorapaxar has recently been approved 
for use in a subset of patients with myocardial infarction and peripheral arterial disease (; Poole 
et al., 2014).  
Platelet activation is a multi-step process, consisting of platelet adhesion, shape change, granule 
secretion and aggregation.  These processes are mediated by a number of cell surface receptors, 
including integrins and ion channels as well as GPCRs.   Activation of these platelet surface 
receptors triggers multiple signalling cascades that synergise to bring about a co-ordinated 
response to rapidly prevent excessive bleeding.  The signalling events underlying platelet 
activation have been comprehensively reviewed elsewhere (Stegner et al., 2011) and are only 
very briefly outlined here focussing on the contribution of GPCRs to this process.  Platelet 
adhesion is initiated by binding of sub-endothelial von Willebrand Factor (VWF) to platelet 
*3,EĮZKLFh causes transient interaction between platelets and the vasculature. Firm adhesion is 
WKHQPHGLDWHGE\WKHFROODJHQUHFHSWRUVĮȕDQG*39,DFWLYDWLRQRIZKLFKpromotes platelet 
spreading and aggregation.  Furthermore, thrombin generated at the site of vascular injury 
activates PAR receptors causing further shape change, aggregation, thromboxane A2 (TXA2) 
generation and secretion of platelet granule cargo.  Positive feedback loops are initiated 
following ADP release from dense granules and TXA2 generation ZKLFKDFWYLD3<DQG73Į
receptors respectively, to potentiate platelet activation.  These platelet activation pathways 
converge to promote activation RI WKH LQWHJULQ Į,,Eȕ ZKLFK WKHQ LV DEOH WR ELQG ILEULQRJHQ
Signalling via activated Į,,Eȕ
 
is the final step of platelet activation, and results in cytoskeletal 
re-organisation and the formation of large, stable platelet aggregates, leading to the generation of 
stable thrombi  (Watson et al., 2005; Rivera et al., 2009). 
GPCRs as targets for anti-platelet drugs 
GPCRs remain the most widely and successfully targeted proteins for therapeutics and a number 
of anti-platelet drugs act, directly or indirectly at GPCRs expressed on the platelet cell surface.  
Alongside aspirin, which reduces thromboxane generation and hence reduces 73Į receptor 
stimulation, P2Y12 antagonists such as clopidogrel and prasugrel remain front-line therapy for a A
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variety of acute coronary syndromes. Interestingly, drugs that inhibit these ADP and 
thromboxane pathways have proved to be more successful antiplatelet drugs, with less adverse 
bleeding effects FRPSDUHG WR LQWHJULQ Į,,bȕ DQtagonists and PAR1 antagonists, which are 
associated with significant bleeding (Cox et al., 2000; Wiviott et al., 2011; Tricoci et al., 2012). 
This is likely due to the fact that ADP and thromboxane A2 are feedback mediators that 
contribute to activation via potentiation of other agonists. By contrast inhibition of PAR1 and 
Į,,bȕ integrin, which are activated by major platelet agonists, may cause a more significant 
inhibition of platelet activity and therefore an increased risk of bleeding.   
Genetic variations associated with anti-platelet therapies targeting GPCRs. 
A key issue associated with both aspirin and P2Y12 antagonists is a high degree of variability in 
inter-patient responsiveness to drug therapy DQG WKDW D SURSRUWLRQ RI SDWLHQWV GLVSOD\ ³GUXJ
UHVLVWDQFH´.  For example, a third of patients taking clopidogrel are non-responsive as assessed 
by platelet function testing (Cattaneo, 2011b).  The significant proportion of aspirin and P2Y12 
receptor antagonist non-responders has led to considerable research into the underlying genetic 
causes of these variations. In the case of aspirin this has largely focused on cycloxygenase-1 
(COX-1) polymorphisms, a number of which have been associated with reduced responsiveness 
to aspirin (Feher et al., 2009).   Clopidogrel resistance meanwhile is largely associated with poor 
metabolism of the prodrug to the active form.  
Clopidogrel is a pro-drug that requires metabolism by cytochrome P450 enzymes to form an 
active metabolite that subsequently binds irreversibly to the P2Y12 receptor.  A number of studies 
have shown that clopidogrel does not effectively inhibit platelet activity in healthy volunteers 
and patients with acute coronary syndrome who have loss-of-function polymorphisms in 
CYP2C19 (Hulot et al., 2006; Giusti et al., 2007).  Interestingly, loss-of-function variation in the 
cytochrome P450 2C19 gene (CYP2C19), caused by a single nucleotide polymorphism 
(rs4244285; c.681 G>A in NM_000769.1) within the coding region that creates a new splice site 
and thus a truncated and catalytically inactive protein, the CYP2C19*2 genotype, accounts for 
12% of the variability in P2Y12 receptor inhibition seen with clopidogrel (Shuldiner et al., 2009).  
These variations in responsiveness led to the development of prasugrel, a structural analogue of 
clopidogrel.  The hepatic metabolism of prasugrel, which produces the same active metabolite A
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that irreversibly antagonizes the P2Y12 receptor, is less complex and therefore less susceptible to 
genetic variations in cytochrome P450 enzymes.   
Responsiveness to anti-platelet agents is also affected by genetic variation in other key platelet 
genes, for example gain of function single nucleotide variations have been described in platelet 
integrins (GP1D DQGĮ,,bȕ(Cambria-Kiely et al., 2002).   Therefore platelet reactivity in the 
general population is significantly influenced by genetic differences in a number of genes that 
reduce drug responsiveness and potentially contribute to an increased risk of adverse 
cardiovascular events.  
Genetic Variation in Platelet GPCRs 
In addition to exploring common genetic variations within the general population, an alternative 
and successful approach to understanding pathophysiological disease mechanisms is the study of 
patients with bleeding disorders. For example, the GHVFULSWLRQRI*ODQ]PDQQ¶V7KURPEDVWKHQLD 
(Glanzmann, 1918) led to the identification of the key platelet integrin, Į,,bȕ (Nurden et al., 
1974).  Similarly, the P2Y12 receptor was cloned in a study which described a patient with a 
bleeding history and a loss of function variation in the P2Y12R gene that encodes P2Y12 
(Hollopeter et al., 2001).  These examples illustrate how the study of rare function disrupting 
variations affecting key platelet proteins can provide important information regarding platelet 
regulation and allow study of variant native proteins in vivo. This is especially important in 
platelets which are anucleate and therefore cannot be subjected to easy genetic approaches to 
change protein expression.   
As part of the Genotyping and Phenotyping of Platelets consortium (GAPP) we have developed 
an approach for the rapid identification and characterization of rare genetic variations causing 
defects within platelet proteins, including GPCRs (Watson et al., 2010; Watson et al., 2013).  
This study has recruited a cohort of patients who attend UK Haemophilia Centres with symptoms 
of mild, lifelong bleeding but who have no demonstrable defect in platelet number or coagulation 
factors. For each study subject platelets were isolated from blood samples and were analysed by 
light transmission aggregation and secretion assays using a wide panel of agonists at different 
concentrations. Test results were compared to reference intervals for each agonist concentration 
determined by measurement of platelet aggregation and secretion in a cohort of healthy volunteer A
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controls without bleeding symptoms (Dawood et al., 2012). The aim of this detailed analysis is 
to identify the defective signalling pathway responsible for a loss of platelet function thus 
allowing targeted sequencing of a subset of genes that form the signalling pathway in which loss-
of-function variants may underlie the platelet dysfunction.  This approach has recently been 
validated following the description of a novel change in the HPS4 gene in a patient with reduced 
hair, eye and skin pigmentation; bleeding phenotype and platelet dysfunction (Jones et al., 2012).  
If a nucleotide variation is identified that predicts loss of protein function then the structure-
function of the variant protein is studied in detail in heterologous cell systems and by further 
analysis of platelets from the study subject. This approach has been highly successful in 
identifying loss of function variants in a number of GPCRs including the P2Y12 and TP-Į
receptors (detailed in Tables 1 and 2) and has provided significant information regarding 
structure-function relationships of these important anti-thrombotic drug targets.  The findings 
from these and other studies are discussed in further detail below. 
Rare Variants of the Thromboxane Receptor  
Thromboxane receptor deficiency (MIM #614009) is inherited in an autosomal recessive or 
dominant manner and has been identified in several individuals from different kindreds who 
display mild mucocutaneous bleeding symptoms (Kamae et al., 2011).  To date, one quantitative 
defect causing reduced TP-Į receptor expression and four qualitative defects caused by TP 
receptor amino acid substitutions have been reported. These naturally occurring variants are 
listed in table 1 and the findings of these studies summarized below.  
 
A nucleotide variation which caused loss of TP-Į receptor expression was first described in a 
patient with a history of mucocutaneous bleeding (Kamae et al., 2011). Sequence analysis of 
TBXA2R in the patient and her father revealed that these individuals were heterozygous for a 
single nucleotide duplication at c.167 (c.167dupG in NM_001060.5) resulting in a frame shift 
from amino acid 58. Corresponding cell lines studies showed that this caused significantly 
reduced receptor expression.   
 
The first qualitative defect in the TP-ĮUHFeptor caused by a missense nucleotide variation in the 
TBX2R gene was reported in 1994 by Hirata et al., (Hirata et al., 1994).  This resulted from an A
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Arg60Leu amino acid substitution at the start of the 1st intracellular loop (Figure 1) and occurred 
in a patient with a history of post-surgical bleeding (Hirata et al., 1994) but has also since been 
described in another kindred with a history of mild bleeding (Fuse et al., 1996; Higuchi et al., 
1999).  The platelets from these affected individuals show absent or reduced aggregation to the 
synthetic thromboxane analogue U46619. In patients homozygous for the Arg60Leu amino acid 
substitution, the defect in aggregation was also accompanied by a reduction in TXA2-induced IP3 
generation and Ca2+ mobilization.  Interestingly, heterozygous Arg60Leu patients whose 
platelets also showed reduced aggregation to TP-ĮUHFHSWRUDJRQLVWVVKRZHGDSSDUHQWO\QRUPDO
calcium mobilization, suggesting a possible additional pro-aggregatory effect of TP-Į UHFHSWRU
activation that is independent of calcium signalling.  Initial expression studies in Chinese 
Hamster Cells (CHOs) showed that co-expression of both the wild-type (WT) receptor with the 
variant Arg60Leu TP-ĮUHFHSWRUZDVDVVRFLDWHGZLWKa reduction in Ca2+ mobilization although 
the signalling ability of the variant receptor alone was not evaluated (Hirata et al., 1994).   These 
conflicting data in cell lines and human platelets merit further investigation.  More recent studies 
have shown that when expressed alone the Arg60Leu TP-Į UHFHSWRU variant has dramatically 
attenuated receptor responses when compared to WT despite comparable ligand binding 
affinities and receptor surface expression (Chakraborty et al., 2013).  Molecular modelling 
indicates that Arg 60 interacts via hydrogen bonds with  Met 126 and Arg 130 in transmembrane 
domain 3 and that this interaction is lost when the Arg is substituted for Leu (Chakraborty et al., 
2013).  Importantly Arg 130 is part of the D/ERY motif (Figure 1) that is highly conserved 
amongst GPCRs (Rovati et al., 2007) and is critical for receptor activation. Therefore it is likely 
that the variant Arg60Leu TP-Į UHFHSWRU is unable to undergo the required conformational 
changes required to promote efficient G protein coupling. This recent modelling data correlate 
with previous mutagenesis studies of the ERY motif within TP-Į which confirmed the 
involvement of Arg 130 in receptor coupling to Gq (Capra et al., 2004).   Mutation of the Arg 
130 to Val resulted in a loss in inositol phosphate accumulation in response to U46619, a 
consequence of defective PLC activation via Gq.     
 
The remaining TBXA2R gene rare variants causing amino acid substitutions in the TP-Į receptor 
protein sequence (Table 1) have been described using the GAPP approach outlined above.  In 
2010 Mumford et al., identified a patient with a history of bruising and prolonged epistaxes since A
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infancy (Mumford et al., 2010).  Platelet aggregation and secretion were reduced in response to 
arachidonic acid and U46619, whereas responses to other agonists were within normal range.  
Sequencing of the TBXA2R gene showed that the patient was heterozygous for a c.190G>A 
variation predicting an Asp304Asn substitution in the 7th transmembrane domain of the receptor 
(Figure1). Ligand binding studies in platelets revealed a 50% reduction in maximal binding to 
the variant Asp304Asn TP-Į receptor compared to WT, without a change in binding affinity.  
Further studies in CHO cells also showed that the variant Asp304Asn TP-Į receptor had a 
significantly impaired ability to bind radioligand despite expression at the cell surface being 
comparable to WT.  These observations suggested that the reduction in TXA2-mediated platelet 
activation in the patient may be due to impaired ligand binding. Interestingly, this Asp304Asn 
substitution occurred in the highly conserved NPXXY motif (Figure 1), where the Asn at 
position 1 is substituted for Asp in 21% of class A GPCRs (Mirzadegan et al., 2003).  High 
resolution structural studies suggest that this motif, which is located near the cytoplasmic end of 
TMD7, interacts with a network of water molecules to weakly stabilize the inactive state of the 
receptor and also allows rapid conformational changes to occur for activation (Rosenbaum et al., 
2009).   
The observation that an Asn residue at position 1 of the NPXXY motif (P 7.49 as identified by 
Ballesteros-Weinstein numbering) might suggest that the substitution of Asp to Asn observed in 
this study would not be functiondisrupting. However, data from two separate mutagenesis studies 
suggest that the Asp and Asn are not interchangeable. In the human gonadotrophin-releasing 
hormone receptor (GnRH) an Asp318Asn mutation impairs G protein coupling (Zhou et al., 
1994).  In addition Johnson and co-workers showed that there were differences in binding to 
ADP-ribosylation factor (ARF) isoforms between GPCRs that possess the NPXXY versus the 
DPXXY motif (Johnson et al., 2006).  It is unclear why the Asp304Asn substitution causes a 
decrease in ligand binding since the majority of studies of variations within the NPXXY motif 
have found differences in receptor activation. The GnRH Asp318Asn substitution showed no 
alterations in ligand binding (Zhou et al., 1994), which suggests that this effect may be specific 
for the thromboxane receptor, although there is some evidence that residue 7.49 (Ballesteros-
Weinstein numbering) interacts via hydrogen bonding with the ligand binding pocket (Li et al., 
2004; Pardo et al., 2007).     A
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More recently, two further function-disrupting TBXA2R gene variations have been identified, 
both predicting amino acid substitutions within the TMD1 (Figure1) (Mumford et al., 2013; 
Nisar et al., 2014).   Interestingly, both these variations reduce TP-Įreceptor expression at the 
cell surface, suggesting an important role for TMD1 in the regulation of anterograde receptor 
traffic. The Trp29Cys substitution was identified in a patient who displayed abnormal post-
surgical bleeding and whose platelets showed reduced aggregation and secretion in response to 
arachidonic acid and U46619.  Ligand binding studies in both patient platelets and in HEK293 
cells expressing the variant receptor showed a reduction in Bmax and Kd, indicating a reduction 
in receptor surface expression and ligand binding affinity.  Further studies showed no change in 
total receptor expression, but a significant reduction in cell surface expression which was 
accompanied by a reduced ability to signal via Gq.   The Trp29 residue (1.37 Ballesteros-
Weinstein numbering), alongside other residues within TMD1 has previously been shown to be 
important for the formation of heterodimers between TP-ĮDQGWKHDOWHUQDWLYHUHFHSWRULVRIRUP
TP-ȕ(Fanelli et al., 2011).  Interestingly, this study showed that a variant TP-ĮUHFHSWRULQZKLFK
a number of key residues within TMD1 (including Trp29 in combination with Ile25, Cys35, 
Val36, Leu39, Leu43, Leu44 and Ser47) were replaced with alanine, resulted in reductions in 
receptor signaling and ligand binding that were comparable to the Trp29Cys variant reported by 
Mumford and colleagues.  Taken together these findings suggest that Trp29 of the TP-Į receptor 
is a key residue contributing to surface expression seen with the TMD1 mutant studied by Fanelli 
and co-workers, possibly by reducing the ability of TP-Į to form functional dimers at the cell 
membrane. Whilst expression of TP-ȕLQSODWHOHWVDW WKHSURWHLQ level is not clear, the first 343 
residues are shared between the two isoforms, therefore is it likely the same residues are 
involved in homodimer formation. Although the ability of the Trp29Cys variant receptor to 
dimerize was not directly studied in the Mumford et al study (Mumford et al., 2012) subsequent 
work has shown that the variant Trp29Cys TP-Į receptor does not interact with the WT TP-ĮDW
the cell surface (unpublished observations). 
 
A further variant of the TP-Į receptor, Asn42Ser, has also been described (Nisar et al., 2014). 
Like the Trp29Cys variant, this substitution also occurs within TMD1 and results in reduced 
surface receptor expression.  This patient had a history of menorrhagia, excessive post-operative 
bleeding and easy bruising, a phenotype indicative of a platelet-function disorder.  The Asn42 A
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residue (1.5 Ballesteros-Weinstein numbering)  is the most conserved residue in class A GPCRs 
and is involved in hydrogen bonding with Gly51, Ala299 and Asp83 in bovine rhodopsin (Smith, 
2010), all of which are conserved in the human TP-Į receptor.  Cell line studies show that the  
Asn42Ser variant TP-Į receptor is retained intracellularly, likely in a trans Golgi network 
(TGN)/ER compartment. Therefore it is likely that interactions with the Asn42 residue are 
required for correct processing and transport of this receptor to the cell surface.  Another notable 
feature of the protein sequence of the TP-Į receptor is the potential presence of an arginine-based 
ER retention motif (RxR; Figure 1) within intracellular loop 3 (ICL3) of the receptor.  These 
motifs regulate anterograde traffic of proteins including GPCRs (Michelsen et al., 2005; 
Cunningham et al., 2012).  The predominately intracellular localisation of this Asn42Ser variant 
and the ability of this site to interact with other amino acids through hydrogen bonding mean that 
this substitution has the potential to impact conformational rearrangement of the receptor.  Such 
rearrangement may expose motifs such as the RxR motif present in ICL3, which may otherwise 
be masked in native WT form.  The consequence of unmasking through conformational 
rearrangement may result in impaired export from the ER to the plasma membrane, as observed 
for the Asn42Ser variant.  This remains to be explored in more detail.         
 
The description of the Asn42Ser mutation takes the number of TP receptor variants identified in 
patients with abnormal bleeding to a total of 5, indicating that these remain rare contributors to 
bleeding risk even in selected populations.  However, study and characterization of these mutants 
have provided key insights into TP receptor structure/function and in particular highlighted the 
role of TMD1 in the regulation of TP cell surface expression.   
Rare Variants of the P2Y12 Receptor  
P2Y12 receptor deficiency (MIM #609821) has been identified as an autosomal dominant or 
recessive disorder characterized by mild to moderate mucocutaneous bleeding and excessive 
bleeding in response to trauma or after surgery (Cattaneo et al., 2003).  The first description of 
genetic variation in P2RY12 occurred in the report describing the cloning of the gene and was a 
heterozygous dinucleotide deletion within the coding region (c.717_718delCA) (Hollopeter et 
al., 2001) in a previously described patient (Nurden et al., 1995) which resulted in a significant 
loss of P2RY12 expression.  Platelets from patients who are heterozygous for a variation that A
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causes loss of P2Y12 receptor expression (see Table 2) display reduced and reversible 
aggregation to ADP and reduced aggregation to sub-maximal concentrations of other agonists. 
Platelet secretion is also reduced due to the positive feedback role of P2Y12 in amplification. 
Therefore the phenotype is similar to the effects seen in patients with a primary secretion defect.  
A number of further patients have now been described with P2Y12 receptor deficiency, which 
have been the subject of several comprehensive reviews (Cattaneo, 2011a; Cattaneo, 2011c) and 
are summarized in Table 2.  
 
The first P2Y12 receptor defect that caused an alteration in receptor function (as opposed to 
absent expression) was reported by Cattaneo and colleagues who described an individual who 
was compound heterozygous for two amino acid substitutions (Arg256Gln and Arg265Trp) in 
the 6th transmembrane domain and the ECL3 of the P2Y12 receptor respectively (Cattaneo et al., 
2003) (Figure 2). The patient had a lifelong history of easy bruising and excessive post-surgical 
bleeding.  Platelet studies showed reduced and reversible aggregation to high concentrations of 
ADP, whilst shape change remained intact. Signalling studies showed a reduced ability to inhibit 
PGE1-induced cAMP generation despite normal ligand binding. Further analysis was also 
carried out on the two children of the index case, both of whom were heterozygous only for the 
Arg265Trp substitution. Interestingly, these showed a reduction in aggregation and signaling at 
low concentrations of ADP but at higher ADP concentrations there was no difference compared 
to healthy controls. Cell line studies, in which the variant Arg256Gln and Arg265Trp P2Y12 
receptors were individually expressed in CHO cells, revealed that both amino acid substitutions 
caused a similar reduction in receptor activation. In subsequent studies in cell line models, the 
Arg256 residue has also been shown to be important for ligand interactions and antagonist 
recognition (Hoffmann et al., 2008; Hoffmann et al., 2009; Mao et al., 2010; Chen et al., 2011; 
Schmidt et al., 2013).  The study by Mao and co-workers showed that both the variant 
Arg256Gln and Arg265Trp P2Y12 receptor expressed in CHO cells were significantly more 
sensitive to blockade by the P2Y12 antagonist AR-C69931MX than the WT receptor.  
Furthermore, the recent description of the P2Y12 crystal structure also showed that Arg256, 
alongside other residues forms the ligand binding pocket and is involved in both antagonist and 
agonist binding (Zhang et al., 2014a; Zhang et al., 2014b).  The discovery of genetic variants A
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that result in alterations in sensitivity to receptor blockade is clearly advantageous to aiding 
rational drug design.   
 
A similar platelet phenotype was observed by Remijn and co-workers who reported a Pro258Thr 
substitution in the P2Y12 receptor in a patient with a history of epistaxis, easy bruising and post 
traumatic bleeding (Remijn et al., 2007) 7KLV SDWLHQW¶V SODWHOHWV DOVR VKRZHG UHGXFHG DQG
reversible aggregation in response to high ADP concentrations, however the exact mechanism by 
which this the Pro258Thr change within the 3rd extracellular loop (Figure 2) affects P2Y12 
receptor function is not known. 
Two further amino acid substitutions in P2Y12 were identified in a cohort of patients who had 
been previously been recruited to the European Molecular and Clinical Markers for the 
Diagnosis and Management of Type 1 von Willebrand Disease (MCMDM-1VWD) study.  Type 
1 von Willebrand Disease is caused by a quantitative reduction in the plasma concentration of 
von Willebrand factor (VWF) which is required for platelet adhesion. The bleeding symptoms 
associated with Type 1 von Willebrand Disease (VWD) are indistinguishable from those seen in 
patients with mild platelet function disorders and show significant inter-individual variation, 
even between members of the same family. Data from the MCMDM-1VWD study have 
confirmed the contribution of genetic loci outside of the VWF locus to the pathogenesis of 
bleeding in type 1 VWD (Goodeve et al., 2007). This raises the possibility that loss-of-function 
variations in genes that affect platelet function may contribute to the severity of bleeding in some 
individuals with type I VWD.   
 
In order to test this hypothesis, P2Y12R from the MCMDM-1VWD index cases and 
geographically matched healthy controls were sequenced as part of the GAPP study. The first of 
the two variant receptors identified was a Lys174Glu substitution in the 2nd extracellular loop of 
the P2Y12 receptor (Daly et al., 2009). Platelets from the patient and two related individuals 
showed reduced aggregation and secretion to ADP. Ligand binding studies revealed a significant 
reduction in the ability of the variant P2Y12 Lys174Glu receptor to bind radioligand compared to 
WT receptor, whilst total and surface expression were not affected.  The 174 lysine residue is 
adjacent to a cysteine residue (Cys175; Figure 2) which has previously been shown to be 
involved in ligand binding (Costanzi et al., 2004; Savi et al., 2006).  Interestingly, the P2Y12 A
cc
ep
te
d
 A
rt
ic
le
This article is protected by copyright. All rights reserved. 
crystal structure suggests that Lys174 does not directly interact with the agonist, but instead 
stabilizes the agonist-bound conformation via the formation of a salt bridge with Glu273 in the 
TMD7 (Zhang et al., 2014a).   
 
A further patient from the MCMDM-1VWD cohort was found to be heterozygous for a 
Pro341Ala substitution in the extreme C terminus of the P2Y12 receptor.  Platelet studies on the 
mother of the patient, who did not have VWD but was heterozygous for the Pro341Ala P2Y12 
receptor substitution, revealed a reduced ability to signal via Gi at low ADP concentrations and a 
reduction in maximal P2Y12 ligand binding (Nisar et al., 2011).    Although there was no effect 
on aggregation to ADP or other agonists, further studies revealed that the variant receptor was 
unable to correctly recycle back to the surface following receptor stimulation and internalization. 
Studies in cells transfected with the variant Pro341Ala P2Y12 receptor revealed that the receptor 
was retained intracellularly in the TGN and rab-7 positive compartments and was not able to 
recycle and resensitize following agonist exposure (Nisar et al., 2011; Cunningham et al., 2013).  
The description of the Pro341Ala substitution was particularly interesting because of its location 
within the PDZ ligand of the P2Y12 receptor (Figure 2). This PDZ ligand consists of a short 
amino acid sequence that is found at the extreme C terminus of a large number of proteins 
including more than 30 GPCRs (Marchese et al., 2008).  GPCR PDZ ligands can bind to a 
number of PDZ domain-containing proteins and these interactions regulate various aspects of 
receptor regulation including stabilization, signaling and trafficking (Weinman et al., 2006). 
Indeed, the P2Y12 receptor has been shown to interact basally with the NHERF1 in a PDZ-
dependent manner (Nisar et al., 2012). Despite a vast number of cell line studies which have 
highlighted the importance of PDZ interactions, this was the first report of a naturally occurring 
mutation that demonstrated the in vivo importance of a GPCR PDZ ligand.   
 
More recently, the in vivo importance of the P2Y12 DRY motif was also demonstrated by the 
description of a naturally occurring variant Arg122Cys P2Y12 receptor identified in a patient who 
had a lifelong history of spontaneous bleeding, and haemorrhage upon surgical challenge (Patel 
et al., 2014).  Importantly this patient was homozygous for the Arg122Cys substitution in the 
P2Y12 receptor and displayed significantly reduced platelet aggregation in response to ADP as a 
result of reduced receptor expression at the platelet cell surface.  Further analysis in cell lines A
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suggested that this was due to enhanced agonist-independent receptor internalization and 
accumulation in lysosomes.  The DRY motif (Figure 2) is a highly conserved region found in 
almost all GPCRs and is known to play a critical role in regulating receptor conformational 
states.  The recent resolution of the P2Y12 crystal structure shows that P2Y12 is atypical for a 
class A GPCR due to the absence of interactions between the DRY motif and helix VI, which 
may explain high constitutive receptor activity (Zhang et al., 2014b).  Data from the R122C 
study suggest that disruption of this motif further prevents stabilization of the P2Y12 receptor in 
an inactive conformation in the absence of agonist, resulting in increased constitutive 
internalization (Patel et al., 2014).  Interestingly, platelet phenotyping of this patient along with 
related family members also showed a reduction in PAR1 peptide-induced platelet activation 
(Patel et al., 2014). Subsequent sequencing analysis of the F2R gene which encodes the PAR1 
receptor found that patient was also homozygous for the PAR1 rs168753 single nucleotide 
polymorphism (SNP) which has previously been shown to result in reduced PAR1 expression in 
platelets (Dupont et al., 2003; Smith et al., 2005).  This is the first description of two GPCRs 
being affected by loss of function mutations that combine to reduce platelet activity. Similar to 
VWD cohort patients described above, this demonstrates the multi-factorial nature of mild 
bleeding disorders.  
 
Genetic variants of other platelet GPCRs 
 
To date there have been no reported function-disrupting rare variants for the P2Y1, PAR1 and 
PAR4 receptors, although common population variations in the genes encoding the PAR1 and 
P2Y1 recptors have been associated with weak alterations in platelet activity. For example, the 
rs168753 variation in F2R, that encodes the PAR1 receptor, is associated with reduced platelet 
activity. The P2Y1 SNP (1622 G/G genotype) has been associated with a reduced anti-platelet 
effect of aspirin (Lordkipanidze et al., 2011). The GAPP consortium has found a single missense 
PAR1 rare variant and one missense PAR4 variant (Stockley et al., in submission) although no 
change in receptor function has yet been detected.  The lack of rare mutations in these receptors 
(that are widely expressed and have key non-platelet functions) suggests that substitutions that 
significantly alter function of these receptors may be incompatible with life.  An inherited defect A
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in the alpha 2A adrenoceptor that is associated with reduced receptor aggregation to epinephrine 
has been described (Rao et al., 1988) however the causative gene defect is unknown.    
 
There are also a number of inhibitory GPCRs expressed on the platelet surface, such as the 
prostanoid receptors, (EP2 and IP) and the adenosine 2A receptor (A2A).  These receptors couple 
to Gs, raise intracellular cAMP levels and inhibit platelet activation via Protein Kinase A.  
Although ADORA2A variants have been associated with a variety of diseases (Deckert et al., 
1996; Hohoff et al., 2007), loss-of-function changes in inhibitory receptors are unlikely to 
contribute to an increased bleeding risk. However cAMP is a vital regulatory pathway in 
platelets and loss-of-function mutations in genes involved in this pathway could contribute to 
increased platelet reactivity and therefore increased risk of adverse cardiovascular events.  
Implications of Receptor Mutations for Mild Bleeding 
Whilst these studies have provided useful information regarding receptor function, it is important 
to note that the presence of a heterozygous variation in a GPCR gene does not always correlate 
with a clinical bleeding phenotype. For example, in the previously reported kindreds with TP-Į
caused by Asp304Asn and Trp29Cys substitutions, the index cases presented with mild bleeding. 
However, in both kindreds, there were other first degree relatives who were also heterozygous 
for these loss-of-function substitutions, but were asymptomatic (Mumford et al., 2010; Mumford 
et al., 2012).  Similarly, patients with P2Y12 receptor deficiency display bleeding symptoms of 
variable severity that does not correlate well with genotype, or the presence of homozygous 
versus heterozygous changes.  These findings highlight the multifactorial nature of mild bleeding 
symptoms and suggest that there may be further unidentified defects in the index cases of these 
kindreds that contribute to the bleeding diathesis.  For example the index case with the 
Pro341Ala P2Y12 receptor substitution also had VWD type 1 disease and a more severe bleeding 
history than his mother who had an identical platelet P2Y12 receptor defect but did not have 
VWD (Nisar et al., 2011).  The requirement for a closed high-pressure cardiovascular system for 
life necessitates multiple pathways for haemostasis with a high degree of redundancy.  Thus, 
whilst studies using a detailed phenotyping approach combined with targeted genotyping 
(Dawood et al., 2012), such as described above can be used to diagnose platelet function 
disorders, wider speculation on the causes of bleeding should be avoided in the absence of whole A
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genome sequencing and validation of various non-platelet genes that are involved in 
haemostasis.   
 
Discussion and Future Perspectives  
Variation in GPCR genes results in the disruption of receptor function in a wide variety of 
human genetic diseases, including mild platelet bleeding disorders. The description and 
characterization of a number of rare thromboxane and P2Y12 receptor variants has provided key 
insights into the physiological significance of GPCR subdomains.  Although there have been a 
number of studies that have undertaken mutation analysis of these receptors, these naturally 
occurring variants provide the opportunity to study the effect of changes such as amino acid 
substitutions in endogenously expressed receptors in human platelets.  Platelets have a clear 
advantage over other cell types as they can be taken repeatedly and with relative ease from 
patients and family members.  Whilst murine knock-out models have been important for 
delineating roles of individual surface receptors in platelet activation and in vivo thrombosis, 
more subtle study of receptor function at the molecular level in platelets is associated with a 
number of technical challenges. For example there is an inherent lack of receptor specific 
antibodies able to detect receptor expression. Furthermore, there are often difficulties in 
translating findings in cell expression studies into platelets because of differences in cell 
machinery, membrane trafficking and receptor expression levels.  
 
Importantly the rare receptor variants described above validate findings found in the vast number 
of cell expression and modeling studies which have previously assigned structure-function 
relationships to particular receptor motifs. For example, rare receptor variants that disrupt the 
NPXXXY, PDZ and DRY motifs (figures 1 & 2) have all been shown to affect endogenous 
receptor function in platelets.  The description of these rare variants that affect ligand binding, 
surface expression, G protein coupling and intracellular trafficking highlights the critical 
importance of each of these processes upon GPCR function, and for the P2Y12 and TP-Į
receptors, maps these functions to specific domains and residues.  This is significant because 
these receptors remain at the forefront of anti-platelet drug therapy. The descriptions of variant 
receptors such as the Arg256Gln/ Arg265Trp P2Y12 receptor that affect antagonist sensitivity 
may aid targeted rational drug design in this area.  Recent data from phase III clinical trials of A
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PAR1 antagonists (Capodanno et al., 2012; Tricoci et al., 2012) confirm the need for more subtle 
approaches to combat the bleeding associated with anti-platelet therapy. Greater insight into how 
platelet GPCRs are regulated may also provide novel mechanisms to prevent excessive platelet 
activation whilst preserving haemostasis.   
 
Genome-wide analysis has shown that variants of platelet receptors, including ADRA2 and 
P2Y12R, are associated with increased platelet reactivity in the normal population (Jones et al., 
2009; Johnson et al., 2010), a finding which has confirmed previous candidate gene studies 
(Kunicki et al., 2012). Recent advances in second generation sequencing technologies mean that 
large numbers of individuals can be rapidly tested for genetic changes in their whole exome or 
through pre-selected candidate genes (Jones et al., 2012). However, it is clear that an integrated 
approach involving detailed phenotyping and cell validation studies are required in order to truly 
dissect out and then demonstrate meaningful changes in platelet activity.  The study of patients 
with mild bleeding has been highly successful in identifying a number of rare GPCR mutants 
that affect receptor function. It is hoped that the extension of this candidate gene-led approach to 
whole exome analysis will provide further information regarding known platelets genes and to 
identify novel regulators of platelet function.   
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LEGENDS 
 
Figure1 
Thromboxane (TP-Į) receptor snake plot.   
Sites of naturally-occurring variants found in patients with a bleeding history are highlighted in 
green.  Key amino-acid regulatory motifs are highlighted in yellow (specifically RXR ER 
retention motif; D/NPXXY motif, E/DRY motif).   
 
Figure 2 
P2Y12 Receptor Snake Plot 
Sites of naturally-occurring variants found in patients with a bleeding history are highlighted in 
green.  Key amino-acid regulatory motifs are highlighted in yellow (specifically E/DRY motif 
and type 1 PDZ ligand).   
 
Table 1.  
Variants of TBXA2R. The numbering used to described coding region variants relates to the Ref 
Seq transcript NM_001060.5. ICL: intracellular loop. TMD: transmembrane domain. 
 
Table 2. 
Variants of P2RY12.  
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Description 
Variation 
in coding 
DNA 
Inheritance Region Defect Reference 
Receptor 
deficiency 
c.167dupG heterozygous  
reduced receptor 
expression 
Kamae et al., 2011 
R60L c.179G>T 
homozygous 
or 
heterozygous 
ICL1 
reduced receptor 
coupling to Gq 
Hirata et al., 1994 & 
Higuchi et al., 1999 
D304N c.190G>A heterozygous TMD7 
reduced ligand 
binding 
Mumford et al., 
2010 
W29C c.87G>C heterozygous TMD1 
reduced surface 
expression 
Mumford et al., 
2012 
N42S c.125A>G heterozygous TMD1 
reduced surface 
expression 
Nisar et al., in 
submission 
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Description 
Variation in 
coding DNA 
Inheritance Region Defect Reference 
Receptor 
deficiency 
c.717_718delCA heterozygous 
no 
protein 
no 
signaling 
via P2Y12 
Nurden et al. 
1995 & 
Hollopeter et 
al. 2001 
Receptor 
deficiency 
c.2T>G homozygous 
no 
protein 
no 
signaling 
via P2Y12 
Shiraga et 
al., 2005 
Receptor 
deficiency 
c.378delC 
haploinsufficiency: 
only 1 variant 
P2RY12 allele 
detected 
no 
protein 
no 
signaling 
via P2Y12 
Fontana et 
al., 2009 
Partial 
receptor 
deficiency 
none detected 
haploinsufficiency: 
only 1 WT P2RY12 
allele detected 
 
reduced 
receptor 
function 
Fontana et 
al., 2009 
R256Q & 
R265W 
c.767G>A; 
793C>T 
compound 
heterozygous 
TMD6; 
ECL3 
reduced 
signaling 
via Gi 
Cattaneo et 
al., 2003 
P258T c.772C>A heterozygous ECL3 
reduced 
receptor 
function 
Remijin et 
al., 2007 
K174E c.520A>G heterozygous ECL2 
reduced 
ligand 
binding 
Daly et al., 
2009 A
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le
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P341A c.1021C>G heterozygous C-term 
defective 
receptor 
trafficking 
Nisar et al., 
2011 
R122C c.365G> homozygous 
ICL2 
DRY 
motif 
enhanced 
constitutive 
activity 
Patel et al., 
in 
submission 
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